itinai content

  • AI News
  • AI Sales
  • Apple AI
  • Biohacking
  • Clinical Trials
  • Compare
  • Computer Vision
  • DeepSense
  • farma
  • Instruments
  • Management
  • Marketing
  • Marktechpost
  • Open AI
  • resume
  • КП
  • Inside Reevo’s $80M Bet to Kill the $10B Frankenstein Stack | David Zhu, Cofounder & CEO

    15 мая, 2026

    The GTM Podcast is available on any major directory, including: Apple Podcasts Spotify YouTube AI is rewriting go-to-market and most companies are still operating with a “Frankenstein stack.” In this episode of GTMnow, we sit down with David Zhu, founder & CEO of Reeva, to unpack how AI-native companies will replace legacy GTM systems, why the… →

    AI Sales
  • Inside Reevo’s $80M Bet to Kill the $10B Frankenstein Stack

    15 мая, 2026

    Listen on YouTube Listen on Apple Listen on Spotify If you spend time on X, you can also watch/listen to the entire episode on X. Brought to you by: One critical and surprisingly complicated decision is naming your startup. Founders often spend weeks chasing the perfect .com, only to overpay or settle for a name… →

    AI Sales
  • Health-related quality of life comparing standard and prolonged time-to-surgery after neoadjuvant chemoradiotherapy for esophageal cancer: results from the multicenter, randomized, controlled NeoRes II trial

    14 мая, 2026

    Standard time-to-surgery after neoadjuvant chemoradiotherapy for esophageal cancer has historically been 4-6 weeks. Observational studies have suggested improved oncological outcomes and health-related quality of life in patients after prolonged time-to-surgery. This study aimed to investigate whether prolonged time-to-surgery is associated with improved health-related quality of life compared to the standard interval. This study is a… →

    Clinical Trials
  • A Phase 1 Oral Mass Balance and Combined Intravenous [14C] Microtracer Study to Characterize the Absorption, Metabolism, Excretion, and Pharmacokinetics of Antitumor Drug E7386 in Humans

    14 мая, 2026

    E7386, an orally active protein-protein interaction inhibitor, is reported to impair the interaction between transcriptional co-activator CREB-binding protein and β-catenin. A competent study design exploring the concomitant dosing routes, sensitive intravenous (IV; [^(14)C]) microtracer technology, and oral [^(14)C] radiolabeled dosing was successfully implemented to determine the absolute bioavailability and the absorption, metabolism, and excretion (AME)… →

    Clinical Trials
  • Acute placebo responsiveness predicts longitudinal expectation effects in antidepressant treatment

    14 мая, 2026

    Positive treatment expectations are known to enhance antidepressant efficacy. Experimental placebo studies aim to provide mechanistic insights into this association, yet their findings have not been clearly linked to clinical expectation effects within individual patients. In a randomized crossover trial, 61 participants with major depressive disorder (31 women, 30 men) completed an emotion classification task… →

    Clinical Trials
  • Providing information to prepare breast cancer patients for their surgical consultation: barriers and recommendations (an analysis from Alliance A231701CD)

    14 мая, 2026

    CONCLUSION: Our study highlights that breast cancer patients want information prior to the consultation, but patient-centered challenges can lead to non-review. When sharing pre-consult information, clinics should communicate how reviewing information can help patients feel less overwhelmed and improve their discussion with the surgeon. →

    Clinical Trials
  • Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy and Renal Impairment: Analyses From HELIOS-B

    14 мая, 2026

    CONCLUSIONS: Vutrisiran may slow eGFR decline and is effective and well-tolerated in patients with ATTR-CM with declining renal function, including those developing CKD stage ≥4. →

    Clinical Trials
  • Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension

    14 мая, 2026

    CONCLUSIONS: Bimekizumab treatment led to rapid and sustained improvements in key patient symptoms and HRQoL to 3 years, emphasising its long-term value in controlling symptoms which profoundly affect patients’ experience and daily lives. →

    Clinical Trials
  • Regulatory B cell expansion and type 1 innate lymphoid cell suppression characterise immune modulation in paediatric lupus nephritis

    14 мая, 2026

    CONCLUSIONS: BAFF inhibition in paediatric LN is associated with rebalancing of innate and adaptive immunity through enhancement of Breg function and suppression of ILC1-driven inflammation. →

    Clinical Trials
  • Prophylactic tranexamic acid for the prevention of postpartum haemorrhage in women with placenta praevia: multicentre, double blind, randomised, placebo controlled, phase 3 trial

    14 мая, 2026

    CONCLUSIONS: In women with placenta praevia who underwent caesarean delivery and received prophylactic oxytocin, treatment with tranexamic acid resulted in a statistically significant yet modest reduction in the incidence of postpartum haemorrhage, with no signal of increased serious adverse events. →

    Clinical Trials
Предыдущая страница
1 … 67 68 69 70 71 … 1 027
Следующая страница